Bevacizumab treatment is associated with imaging and hearing responses in progressive vestibular schwannoma (VS) caused by NF2-related schwannomatosis (NF2-SWN).
However, its effect on co-existing intracranial non-vestibular schwannomas (NVS) and meningiomas is unclear.
